Ed Schnipper

Ed is the Head of Clinical Development at X-37. He has been working in the pharmaceutical industry for several decades and has been involved in the clinical development of many drugs from IND to NDA at both large and small pharmaceutical companies.

Ed has held senior management positions at Hoffmann-LaRoche, Alza, Cellgate, and Novacea, where he managed clinical trials across several therapeutic areas including approvals of drugs such as Roferon A, Vesanoid, Saquinavir, Doxil, Duros Leuprolide, and Concerta.

Ed was also a founding member of Velocity Pharmaceutical Development and helped manage the clinical program for Tigercat Pharma leading to the successful IPO of the company now known as Menlo Therapeutics. He is also involved in the development of a new treatment for pulmonary arterial hypertension at Corsair Pharma.

Ed holds an MD degree from Georgetown University. He completed a fellowship in Hematology at New York University and was an oncology fellow at Memorial – Sloan Kettering Cancer Center.